Huntleigh Advisors Inc. bought a new position in shares of Kamada Ltd. (NASDAQ:KMDA - Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 130,625 shares of the biotechnology company's stock, valued at approximately $863,000. Huntleigh Advisors Inc. owned 0.23% of Kamada as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in KMDA. JPMorgan Chase & Co. purchased a new stake in Kamada during the 4th quarter worth approximately $67,000. NewEdge Advisors LLC increased its position in shares of Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock valued at $143,000 after purchasing an additional 8,260 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Kamada by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock valued at $178,000 after purchasing an additional 1,549 shares during the last quarter. Finally, Aristides Capital LLC increased its position in shares of Kamada by 12.1% in the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock valued at $387,000 after purchasing an additional 6,850 shares during the last quarter. 20.38% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on KMDA shares. Benchmark reissued a "buy" rating and issued a $15.00 price objective on shares of Kamada in a research report on Thursday, May 15th. Sidoti raised shares of Kamada to a "hold" rating in a research report on Thursday, May 8th. Finally, Wall Street Zen raised shares of Kamada from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, May 21st.
Get Our Latest Stock Analysis on KMDA
Kamada Trading Down 2.2%
Shares of NASDAQ KMDA traded down $0.17 during mid-day trading on Monday, reaching $7.71. The company had a trading volume of 63,953 shares, compared to its average volume of 96,223. The firm has a 50 day simple moving average of $7.05 and a two-hundred day simple moving average of $6.91. The stock has a market cap of $443.40 million, a P/E ratio of 26.59, a PEG ratio of 0.96 and a beta of 0.96. Kamada Ltd. has a 52-week low of $5.08 and a 52-week high of $9.16.
Kamada (NASDAQ:KMDA - Get Free Report) last posted its earnings results on Wednesday, May 14th. The biotechnology company reported $0.07 EPS for the quarter, meeting analysts' consensus estimates of $0.07. The firm had revenue of $44.02 million for the quarter, compared to the consensus estimate of $154.06 million. Kamada had a net margin of 9.60% and a return on equity of 6.31%. On average, equities analysts expect that Kamada Ltd. will post 0.23 EPS for the current year.
Kamada Company Profile
(
Free Report)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
Further Reading

Before you consider Kamada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.
While Kamada currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.